Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC cut its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 14.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,908 shares of the technology company’s stock after selling 18,507 shares during the period. Fisher Asset Management LLC owned 0.10% of Cogent Biosciences worth $865,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of COGT. Mirae Asset Global Investments Co. Ltd. boosted its stake in Cogent Biosciences by 38.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,959 shares of the technology company’s stock worth $43,000 after purchasing an additional 1,104 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in Cogent Biosciences during the 4th quarter valued at approximately $93,000. Victory Capital Management Inc. acquired a new stake in Cogent Biosciences during the 3rd quarter valued at approximately $113,000. Dynamic Technology Lab Private Ltd acquired a new stake in Cogent Biosciences during the 3rd quarter valued at approximately $134,000. Finally, Virtu Financial LLC acquired a new stake in Cogent Biosciences during the 3rd quarter valued at approximately $147,000.

Cogent Biosciences Price Performance

NASDAQ:COGT opened at $7.67 on Thursday. The firm has a market cap of $873.23 million, a price-to-earnings ratio of -3.09 and a beta of 1.81. The company has a 50 day moving average price of $8.13 and a 200-day moving average price of $9.51. Cogent Biosciences, Inc. has a 1-year low of $5.73 and a 1-year high of $12.61.

Analyst Ratings Changes

Several brokerages have commented on COGT. Robert W. Baird decreased their price objective on shares of Cogent Biosciences from $10.00 to $8.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. HC Wainwright decreased their price objective on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Needham & Company LLC restated a “hold” rating on shares of Cogent Biosciences in a research note on Wednesday, February 26th. JPMorgan Chase & Co. lifted their price objective on shares of Cogent Biosciences from $19.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, Wedbush restated a “neutral” rating and set a $11.00 price objective on shares of Cogent Biosciences in a research note on Tuesday, February 25th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.